Co-Diagnostics, Inc. (CODX)
NASDAQ: CODX · Real-Time Price · USD
0.3847
+0.0057 (1.50%)
At close: Oct 13, 2025, 4:00 PM EDT
0.4000
+0.0153 (3.98%)
Pre-market: Oct 14, 2025, 5:39 AM EDT
Co-Diagnostics Revenue
Co-Diagnostics had revenue of $162.91K in the quarter ending June 30, 2025, a decrease of -93.87%. This brings the company's revenue in the last twelve months to $1.00M, down -89.02% year-over-year. In the year 2024, Co-Diagnostics had annual revenue of $3.92M, down -42.53%.
Revenue (ttm)
$1.00M
Revenue Growth
-89.02%
P/S Ratio
12.13
Revenue / Employee
$7,603
Employees
132
Market Cap
18.52M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.92M | -2.90M | -42.53% |
Dec 31, 2023 | 6.81M | -27.41M | -80.09% |
Dec 31, 2022 | 34.22M | -63.67M | -65.04% |
Dec 31, 2021 | 97.89M | 23.33M | 31.30% |
Dec 31, 2020 | 74.55M | 74.34M | 34,579.90% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CODX News
- 21 hours ago - Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit - PRNewsWire
- 13 days ago - Co-Diagnostics, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30 - PRNewsWire
- 25 days ago - Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 26 days ago - Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 4 weeks ago - Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains - PRNewsWire
- 4 weeks ago - Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit - PRNewsWire
- 2 months ago - Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C. - PRNewsWire
- 2 months ago - Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha